Heslop HE - Search Results

1

T-cell-based therapies for malignancy and infection in childhood.

Ahmed N, Heslop HE, Mackall CL. Ahmed N, et al. Among authors: heslop he. Pediatr Clin North Am. 2010 Feb;57(1):83-96. doi: 10.1016/j.pcl.2009.11.002. Pediatr Clin North Am. 2010. PMID: 20307713 Free PMC article. Review.

2

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. Gottschalk S, et al. Among authors: heslop he. Blood. 2001 Feb 15;97(4):835-43. doi: 10.1182/blood.v97.4.835. Blood. 2001. PMID: 11159505 Free article.

3

The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.

Savoldo B, Heslop HE, Rooney CM. Savoldo B, et al. Among authors: heslop he. Leuk Lymphoma. 2000 Nov;39(5-6):455-64. doi: 10.3109/10428190009113376. Leuk Lymphoma. 2000. PMID: 11342329 Review.

4

Gene therapy for paediatric leukaemia.

Rousseau RF, Bollard CM, Heslop HE. Rousseau RF, et al. Among authors: heslop he. Expert Opin Biol Ther. 2001 Jul;1(4):663-74. doi: 10.1517/14712598.1.4.663. Expert Opin Biol Ther. 2001. PMID: 11727502 Review.

5

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.

Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM. Liu Z, et al. Among authors: heslop he. Recent Results Cancer Res. 2002;159:123-33. doi: 10.1007/978-3-642-56352-2_15. Recent Results Cancer Res. 2002. PMID: 11785836

6

Immunotherapy to reconstitute immunity to DNA viruses.

Gahn B, Hunt G, Rooney CM, Heslop HE. Gahn B, et al. Among authors: heslop he. Semin Hematol. 2002 Jan;39(1):41-7. doi: 10.1053/shem.2002.29252. Semin Hematol. 2002. PMID: 11799528 Review.

7

Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation.

Wagner HJ, Rooney CM, Heslop HE. Wagner HJ, et al. Among authors: heslop he. Biol Blood Marrow Transplant. 2002;8(1):1-8. doi: 10.1053/bbmt.2002.v8.pm11846351. Biol Blood Marrow Transplant. 2002. PMID: 11846351 Free article. Review.

8

Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.

Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. Savoldo B, et al. Among authors: heslop he. Blood. 2002 Dec 1;100(12):4059-66. doi: 10.1182/blood-2002-01-0039. Epub 2002 Aug 1. Blood. 2002. PMID: 12393655 Free article. Clinical Trial.

9

Genetically engineered T-cells for adoptive immunotherapy.

Pule M, Bollard CM, Heslop HE. Pule M, et al. Among authors: heslop he. Curr Opin Mol Ther. 2002 Oct;4(5):467-75. Curr Opin Mol Ther. 2002. PMID: 12435048 Review.

10

Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.

Bollard CM, Savoldo B, Rooney CM, Heslop HE. Bollard CM, et al. Among authors: heslop he. Acta Haematol. 2003;110(2-3):139-48. doi: 10.1159/000072463. Acta Haematol. 2003. PMID: 14583674 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

424 results

Search Page

Filters